B-CELL NON-HODGKIN'S LYMPHOMA Clinical Trials

51 clinical trials for B-CELL NON-HODGKIN'S LYMPHOMA across international registries, including 16 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia — RECRUITING · PHASE1
• A PHASE 1/2 OPEN-LABEL, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND CLINICAL ACTIVITY OF GSK5926371 IN ADULT PARTICIPANTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (B-NHL) — RECRUITING · PHASE1
• Long-Term Follow-up Study — RECRUITING
• In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies — RECRUITING · PHASE1
• JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma — RECRUITING · PHASE2
• T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) — RECRUITING · PHASE1
• AN OPEN-LABEL, MULTICENTER, PHASE 1 TRIAL TO EVALUATE THE SAFETY, PHARMAKONETICS, AND ANTI-TUMOUR ACTIVITY OF TLN-121 AS A SINGLE AGENT AND IN COMBINATION WITH OTHER ANTI-LYMPHOMA AGENTS, IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN LYMPHOMAS — RECRUITING · PHASE1
• A MODULAR PHASE II, SINGLE-ARM, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AZD0486 IN PARTICIPANTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA (SOUNDTRACK-B) — RECRUITING · PHASE2
• A PHASE 1B MULTICENTER, OPEN-LABEL, STUDY OF JNJ-90014496, AN AUTOLOGOUS CD19/CD20 BI-SPECIFIC CAR-T CELL THERAPY IN ADULT PARTICIPANTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA — RECRUITING · PHASE1
• A PHASE I COHORT DOSE ESCALATION AND EXPANSION TRIAL TO DETERMINE THE SAFETY, TOLERANCE, MAXIMUM TOLERATED DOSE, AND PRELIMINARY ANTINEOPLASTIC ACTIVITY OF IKS03, A CD19-TARGETING ANTIBODY DRUG CONJUGATE (ADC) IN PATIENTS WITH ADVANCED B CELL NON-HODGKIN LYMPHOMAS (NHL) — RECRUITING · PHASE1
• A PHASE 2, OPEN-LABEL, SINGLE-ARM, MULTICOHORT, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF JCAR017 IN ADULT SUBJECTS WITH RELAPSED OR REFRACTORY INDOLENT B-CELL NON-HODGKIN LYMPHOMA (NHL) — RECRUITING · PHASE2
• A PHASE 1, MULTICENTER, OPEN-LABEL STUDY OF CC-97540, CD19-TARGETED NEX-T CHIMERIC ANTIGEN RECEPTOR (CAR) T CELLS, IN SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA — RECRUITING · PHASE1
• A PHASE I MASTER PROTOCOL OF NOVEL COMBINATION THERAPY FOR PATIENTS WITH RELAPSED OR REFRACTORY AGGRESSIVE B-CELL LYMPHOMA. — RECRUITING · PHASE1
• AN OPEN-LABEL, PHASE 1B/2 STUDY OF ACALABRUTINIB ALONE OR IN COMBINATION THERAPY IN SUBJECTS WITH B-CELL NON-HODGKIN LYMPHOMA — RECRUITING · PHASE1
• AN OPEN-LABEL, MULTICENTER, PHASE I/IB TRIAL EVALUATING THE SAFETY AND PHARMACOKINETICS OF ESCALATING DOSES OF BTCT4465A AS A SINGLE AGENT AND COMBINED WITH ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NONHODGKIN'S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA. — RECRUITING · PHASE1
• TISAGENLECLEUCEL VERSUS STANDARD OF CARE IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY AGGRESSIVE B-CELL NON-HODGKIN LYMPHOMA: A RANDOMIZED, OPEN LABEL, PHASE III TRIAL (BELINDA) — RECRUITING · PHASE3
• A study to learn how safe and tolerable odronextamab and cemiplimab are in adult patients with B-cell malignancies — OTHER · PHASE1
• A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma — COMPLETED · PHASE1
• Clinical Study of XP-006 mRNA Vaccine for R/R B-NHL — NOT_YET_RECRUITING · PHASE1
• A Study of C-CAR039 Treatment in Subjects With r/r NHL SubjectsNon-Hodgkin's Lymphoma — COMPLETED · PHASE1
• Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and Lymphoma — TERMINATED · PHASE1
• HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma — COMPLETED · PHASE1
• A Phase I Clinical Trial of RS001 in Patients with Relapsed/Refractory B-Cell Malignancies — NOT_YET_RECRUITING · PHASE1
• CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) — OTHER · PHASE1
• Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL — COMPLETED · PHASE2
• A Phase I Safety, PK and PD Study of KW-2478 in Patients With Multiple Myeloma, Chronic Lymphocytic Leukaemia or B-cell Non-Hodgkin's Lymphoma — COMPLETED · PHASE1
• A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL — NOT_YET_RECRUITING · PHASE1
• A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma — OTHER · PHASE1
• A PHASE 1, OPEN-LABEL, MULTICENTER, DOSE ESCALATION STUDY OF PRT1419 INJECTION AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MYELOID OR B-CELL MALIGNANCIES — COMPLETED · PHASE1
• A Clinical Study of Injectable IMM0306 in Combination With Lenalidomide — OTHER · PHASE1
• Novel CAR-T Cell Therapy in the Treatment of Hematopoietic and Lymphoid Malignancies — WITHDRAWN · PHASE1
• Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL) — SUSPENDED · PHASE1
• Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell NHL — OTHER · PHASE1
• Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma — OTHER · PHASE2
• Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL — COMPLETED · PHASE3
• A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma — COMPLETED · PHASE1
• LONG-TERM FOLLOW-UP STUDY FOR PARTICIPANTS OF KITE SPONSORED INTERVENTIONAL STUDIES TREATED WITH GENE MODIFIED CELLS — NOT_YET_RECRUITING
• A PHASE 1, OPEN-LABEL, DOSE-ESCALATION AND DOSE-EXPANSION STUDY OF NL-201 IN PATIENTS WITH B-CELL LYMPHOMA, HODGKIN LYMPHOMA, OR MULTIPLE MYELOMA — NOT_YET_RECRUITING · PHASE1
• CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients. — SUSPENDED · PHASE1
• A Phase 1/2 Study of CT120 in Patient With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma — NOT_YET_RECRUITING · PHASE1
• A PHASE IB/II OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF MOSUNETUZUMAB IN COMBINATION WITH TIRAGOLUMAB WITH OR WITHOUT ATEZOLIZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA. — COMPLETED · PHASE1
• Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226) — OTHER · PHASE2
• Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia — COMPLETED · PHASE1
• A PHASE II, SINGLE ARM, MULTICENTER OPEN LABEL TRIAL TO DETERMINE THE SAFETY AND EFFICACY OF TISAGENLECLEUCEL IN PEDIATRIC PATIENTS WITH RELAPSED OR REFRACTORY MATURE B-CELL NON-HODGKIN LYMPHOMA (NHL) (BIANCA) — COMPLETED · PHASE2
• Does CMV Induced Changes in NK Lymphocyte Biology Influence the Effectiveness of Antibody Therapy Used to Treat B Cell Lymphoproliferative Diseases? — OTHER
• Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL) — OTHER · PHASE2
• A PHASE 2/3 MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF BLINATUMOMAB IN SUBJECTS WITH RELAPSED/REFRACTORY AGGRESSIVE B-CELL NON HODGKIN LYMPHOMA — COMPLETED · PHASE2
• Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL — COMPLETED · PHASE2
• A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma — OTHER · PHASE2
• Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma. — COMPLETED · PHASE1

Refine this search